Product information and disease descriptionProduct descriptionProduct information
Special populations
12 evidence topics · 11 sources
Subcutaneous formulation: adults with type 2 diabetes in VANQUISH-2
Oral formulation: adults with type 2 diabetes in SUNRISE-2
Subcutaneous formulation: adults with diabetes excluded from VANQUISH-1 and the phase 2 trial
“Participants with BMI > 50 kg/m” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“or with certain medical conditions, including diabetes, were not eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral formulation: adults with diabetes excluded from SUNRISE-1
Pediatric participants: minimum age in the phase 3 trials
Pediatric participants: clinical data with either formulation
No evidence found.
Subcutaneous formulation: age range in the phase 1 study
Oral formulation: age of participants in the phase 2 trial
Hepatic impairment: exclusion criterion in the maintenance study
Renal or hepatic impairment: pharmacokinetic data with either formulation
No evidence found.
Pregnancy and contraception: requirements in the phase 1 studies
Pregnancy and lactation: clinical data with either formulation
No evidence found.